Mayo Clinic (Jacksonville)
Jacksonville, FL
Filters
Save & Share
Clear Filters
Diagnosis
Purpose of Trial
Filter and find trials based on their purpose.
MDS Centers of Excellence
Accepting patients
DISC-0974
A Phase 1b/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Learn more- Monoclonal Antibody
- Hemojuvelin (HJV)
- Monotherapy
- Randomization
- Phase 1/2
Accepting patients
Phase 1/2 Multicenter, Open-Label Study of CTX-712 in Patients With Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Learn more- CLK Inhibitor
- Phase 1/2
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trialsAccepting patients
Venetoclax in Combination With ASTX727
Venetoclax in Combination With ASTX727, an All-ORal Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN With Excess Blasts (VICTORY-MDS/MPN): A Randomized, Phase 2 Trial
Learn more- BCL-2 Inhibitor
- Hypomethylating Agents (HMA)
- Phase 2
Not yet accepting
CYCLE-1
Open-label, Phase I, Multi-center Study to Determine in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients the Recommended Dose of CYAD-02 After a Non-myeloablative Preconditioning Chemotherapy Followed by a Potential Consolidation Cycle
Learn more- CAR T Cell
- Phase 1
Accepting patients
OPTIMIZE
A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Learn more- Allogeneic Stem Cell Transplant
- Phase 2
Accepting patients
Bone Marrow Failure Clinic Study
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
Learn more- Observational Trial
Not yet accepting
SENTI-202
SENTI-202-101: A Phase 1, Multicenter, Open-Label Study of SENTI-202, a Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy, in Subjects With CD33 and/or FLT3 Expressing Hematological Malignancies
Learn more- Natural Killer Cells (Allogeneic)
- CD33
- FLT3
- Phase 1
Accepting patients
Cancer CARE Beyond Walls
Cancer CARE Beyond Walls - A Pilot of a Randomized, Pragmatic Trial of Cancer Directed Therapy Administration in the Patients' Homes Versus in Clinic
Learn more- Randomization
- Phase 2